2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.79 USD
-0.26 (-5.15%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.78 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
TSVT 4.79 -0.26(-5.15%)
Will TSVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TSVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TSVT
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
TSVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
Other News for TSVT
TSVT Makes Notable Cross Below Critical Moving Average
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
Leerink Partners Keeps Their Buy Rating on 2seventy bio (TSVT)
Analysts Offer Insights on Healthcare Companies: 2seventy bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)